<DOC>
	<DOC>NCT02248142</DOC>
	<brief_summary>Study to evaluate treatment effect of pramipexole on RLS severity as measured by IRLS, CGI-I and RLS-6 and to evaluate the time needed to reach maintenance dose of Pramipexole (PPX)</brief_summary>
	<brief_title>Observational Study of SifrolÂ® in Patients With Primary Restless Legs Syndrome (RLS)</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>Patients suffering from primary RLS who are planned to be initiated on treatment with pramipexole as part of the routine care could be included into the study Patients not pretreated with any dopaminergic agent (de novo patients) or patients pretreated with dopaminergic medication Male or female patients of any age Treating physicians are asked to consider the regulations described in the Summary of Product Characteristics (SPC) for the treatment with pramipexole</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>